CD163 and Behcet disease: Consistent with M1 macrophages, BD serum-treated macrophages expressed a higher level of CD86 (65.1 ± 16.1% vs 39.3 ± 18.3%, p<0.05), a lower level of CD163 (2.4 ± 1.6% vs 6.7 ± 2.1%, p<0.01), and produced higher levels of IL-12 (164.0 ± 100.0 vs 8.3 ± 4.3 pg/ml, p<0.01) and TNF-α (253.1 ± 205.2 vs 22.3 ± 14.0 pg/ml, p<0.05) than M0 macrophages, which were not observed in HC serum-treated macrophages (Fig. 1A–D, Supplemental Figure S2 and S3).